Eledon Pharmaceuticals Statistics
Total Valuation
ELDN has a market cap or net worth of $58.32 million. The enterprise value is $8.45 million.
| Market Cap | 58.32M |
| Enterprise Value | 8.45M |
Important Dates
The next estimated earnings date is Thursday, May 9, 2024, after market close.
| Earnings Date | May 9, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
ELDN has 24.20 million shares outstanding. The number of shares has increased by 72.34% in one year.
| Shares Outstanding | 24.20M |
| Shares Change (YoY) | +72.34% |
| Shares Change (QoQ) | -17.87% |
| Owned by Insiders (%) | 5.43% |
| Owned by Institutions (%) | 38.75% |
| Float | 18.02M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 2.19 |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.71 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 14.41, with a Debt / Equity ratio of 0.00.
| Current Ratio | 14.41 |
| Quick Ratio | n/a |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -46.20% and return on invested capital (ROIC) is -51.31%.
| Return on Equity (ROE) | -46.20% |
| Return on Assets (ROA) | -43.10% |
| Return on Capital (ROIC) | -51.31% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$2.02M |
| Employee Count | 20 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +5.02% in the last 52 weeks. The beta is 0.93, so ELDN's price volatility has been similar to the market average.
| Beta (1Y) | 0.93 |
| 52-Week Price Change | +5.02% |
| 50-Day Moving Average | 1.84 |
| 200-Day Moving Average | 1.56 |
| Relative Strength Index (RSI) | 63.06 |
| Average Volume (30 Days) | 97,895 |
Short Selling Information
The latest short interest is 31,133, so 0.13% of the outstanding shares have been sold short.
| Short Interest | 31,133 |
| Short Previous Month | 106,872 |
| Short % of Shares Out | 0.13% |
| Short % of Float | 0.17% |
| Short Ratio (days to cover) | 0.25 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -43.00M |
| Pretax Income | -40.33M |
| Net Income | -40.33M |
| EBITDA | -39.95M |
| EBIT | -40.33M |
| Earnings Per Share (EPS) | -$1.64 |
Balance Sheet
The company has $51.10 million in cash and $383,000 in debt, giving a net cash position of $50.72 million or $2.10 per share.
| Cash & Cash Equivalents | 51.10M |
| Total Debt | 383,000 |
| Net Cash | 50.72M |
| Net Cash Per Share | $2.10 |
| Equity / Book Value | 83.42M |
| Book Value Per Share | 3.45 |
| Working Capital | 52.23M |
Cash Flow
| Operating Cash Flow | -39.53M |
| Capital Expenditures | n/a |
| Free Cash Flow | -39.53M |
| FCF Per Share | -$1.61 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ELDN does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -72.34% |
| Shareholder Yield | -72.34% |
| Earnings Yield | -68.16% |
| FCF Yield | -66.81% |
Analyst Forecast
The average price target for ELDN is $10.67, which is 342.74% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $10.67 |
| Price Target Difference | 342.74% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | -8.70% |
Stock Splits
The last stock split was on October 5, 2020. It was a reverse split with a ratio of 1:18.
| Last Split Date | Oct 5, 2020 |
| Split Type | Reverse |
| Split Ratio | 1:18 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |